Rossi Daniele Claudio, Ribi Camillo, Guex-Crosier Yan
Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Ophthalmology Department, University of Lausanne, Switzerland.
Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland.
Swiss Med Wkly. 2019 Mar 10;149:w20025. doi: 10.4414/smw.2019.20025. eCollection 2019 Feb 25.
Ocular inflammations such as uveitis and scleritis can lead to significant visual impairment if not treated properly. To limit potentially sight-threatening complications, good control of the inflammation in the acute phase is necessary. Corticosteroids have been the mainstay of ocular therapies for many years, but high doses of corticosteroids, which are required to maintain quiescence in severe uveitis, can be associated with many systemic and ocular complications. In order to limit steroid side-effects, classic immunosuppressant and immunobiologic agents have been widely used as steroid-sparing agents. In this review, we summarise the immunosuppressive drug therapy utilised in the treatment of ocular inflammatory diseases.
葡萄膜炎和巩膜炎等眼部炎症如果治疗不当，可能会导致严重的视力损害。为了限制潜在的视力威胁性并发症，急性期炎症的良好控制是必要的。多年来，皮质类固醇一直是眼部治疗的主要药物，但在严重葡萄膜炎中维持病情静止所需的高剂量皮质类固醇可能会引发许多全身和眼部并发症。为了限制类固醇的副作用，经典免疫抑制剂和免疫生物制剂已被广泛用作类固醇节约剂。在本综述中，我们总结了用于治疗眼部炎症性疾病的免疫抑制药物疗法。
